Thursday, July 9, 2026

pharma · Chronic Inflammatory Demyelinating Polyneuropathy · Multifocal Motor Neuropathy · DNTH

Dianthus Therapeutics, Inc

Dianthus Therapeutics, Inc patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

New York City, USA HQ
111 Employees
Public company Type
DNTH · NYSE Ticker
Company details
Status
Public
HQ
New York City, USA
Employees
111
Programs
6
Drugs
12
Patents
2
Intelligence · Patents

Dianthus Therapeutics, Inc patents

2 pharmaceutical patents indexed for Dianthus Therapeutics, Inc. 0 expire within 24 months.

Dianthus Therapeutics, Inc has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12252550

    Antibodies that bind to C1S and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12110344

    Antibodies that bind to cis and uses thereof

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Dianthus Therapeutics, Inc have?

2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Dianthus Therapeutics, Inc patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.